乌司他丁与生长抑素治疗重症急性胰腺炎临床疗效观察(1)
摘要：目的 比較乌司他丁和生长抑素治疗重症急性胰腺炎的临床疗效。方法 选择我院2017年7月～2018年7月收治的68例重症急性胰腺炎患者，随机分为对照组32例和观察组36例，两组患者均接受常规治疗，对照组在此基础上应用生长抑素治疗，观察组使用乌司他丁治疗。记录两组患者上腹部压痛缓解时间、腹痛恢复时间、血淀粉酶恢复时间，IL-6、IL-8、IL-10、TNF-α改善水平，比较两组治疗有效率。结果 观察组患者的上腹部压痛缓解时间、腹痛恢复时间、血淀粉酶恢复时间均少于对照组，差异有统计学意义(P<0.05);观察组患者的IL-6、IL-8、IL-10、TNF-α改善效果均优于对照组，差异有统计学意义(P<0.05);观察组治疗有效率为94.44%，高于对照组的75.00%，差异有统计学意义(P<0.05)。结论 应用乌司他丁为重症急性胰腺炎患者治疗可有效改善各项炎症介质，缩短各项指标和症状的改善时间，临床应用可行性高。
关键词：乌司他丁;重症急性胰腺炎;生长抑素
, 百拇医药
中图分类号：R576 文献标识码：A DOI：10.3969/j.issn.1006-1959.2019.01.050
文章编号：1006-1959(2019)01-0160-02
Clinical Efficacy of Ulinastatin and Somatostatin in the Treatment of Severe Acute Pancreatitis
LIU Yun，YU Hong-bo
(Department of Gastroenterology，Dalian Jiuzhou Century Hospital，Dalian 116400，Liaoning，China)
, 百拇医药
Abstract：Objective To compare the clinical efficacy of ulinastatin and somatostatin in the treatment of severe acute pancreatitis.Methods 68 patients with severe acute pancreatitis admitted to our hospital from July 2017 to July 2018 were randomly divided into control group (n=32) and observation group (n=36). Both groups received routine treatment. The control group was based on this. Treatment with somatostatin was given and the observation group was treated with ulinastatin. The remission time of abdominal pain， the recovery time of abdominal pain， the recovery time of blood amylase， the improvement of IL-6， IL-8， IL-10 and TNF-α were recorded in the two groups.Results The pain relief time， abdominal pain recovery time and blood amylase recovery time of the observation group were lower than those of the control group， the difference was statistically significant (P<0.05).The improvement of IL-6， IL-8， IL-10 and TNF-α in the observation group was better than that in the control group，the difference was statistically significant (P<0.05). The effective rate of the observation group was 94.44%，compared with 75.00% of the control group， the difference was statistically significant (P<0.05).Conclusion The application of ulinastatin in patients with severe acute pancreatitis can effectively improve various inflammatory mediators， shorten the improvement time of various indicators and symptoms， and has high clinical application feasibility., 百拇医药(刘云 于洪波)
关键词：乌司他丁;重症急性胰腺炎;生长抑素
, 百拇医药
中图分类号：R576 文献标识码：A DOI：10.3969/j.issn.1006-1959.2019.01.050
文章编号：1006-1959(2019)01-0160-02
Clinical Efficacy of Ulinastatin and Somatostatin in the Treatment of Severe Acute Pancreatitis
LIU Yun，YU Hong-bo
(Department of Gastroenterology，Dalian Jiuzhou Century Hospital，Dalian 116400，Liaoning，China)
, 百拇医药
Abstract：Objective To compare the clinical efficacy of ulinastatin and somatostatin in the treatment of severe acute pancreatitis.Methods 68 patients with severe acute pancreatitis admitted to our hospital from July 2017 to July 2018 were randomly divided into control group (n=32) and observation group (n=36). Both groups received routine treatment. The control group was based on this. Treatment with somatostatin was given and the observation group was treated with ulinastatin. The remission time of abdominal pain， the recovery time of abdominal pain， the recovery time of blood amylase， the improvement of IL-6， IL-8， IL-10 and TNF-α were recorded in the two groups.Results The pain relief time， abdominal pain recovery time and blood amylase recovery time of the observation group were lower than those of the control group， the difference was statistically significant (P<0.05).The improvement of IL-6， IL-8， IL-10 and TNF-α in the observation group was better than that in the control group，the difference was statistically significant (P<0.05). The effective rate of the observation group was 94.44%，compared with 75.00% of the control group， the difference was statistically significant (P<0.05).Conclusion The application of ulinastatin in patients with severe acute pancreatitis can effectively improve various inflammatory mediators， shorten the improvement time of various indicators and symptoms， and has high clinical application feasibility., 百拇医药(刘云 于洪波)